Solara Active Pharma Sciences Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.4K Cr

The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale. The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance.

From Solara Active Pharma Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹617

Market Cap

₹2.4K Cr

P/E Ratio

573.4

How does Solara Active Pharma Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Solara Active Pharma Sciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹387 Cr, net profit ₹10 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale.
→New product filings through R&D (4-5 DMFs annually) will start contributing around FY29-FY30, driving medium- to long-term growth.
→Incremental revenue growth will be supported by better operational efficiency, yield improvement, and capacity debottlenecking within existing facilities (around 30% spare capacity available).
→The company prefers investing resources in high-margin base business rather than commodity segments like ibuprofen, which have shown negative returns.
→Management is hopeful to sustain and improve the recent positive quarterly performance and aims for 15-20% plus growth in the near term but is cautious about giving explicit guidance.
→Long-term strategic growth will be driven by new geographies, increased market share, and enhanced product pipeline, supported by a strong leadership team.

📈 Profitability & Margins

→The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance.
→Q4 FY26 saw strong momentum with 12% QoQ revenue growth and 65% QoQ EBITDA growth, driven by the base business operating at ~26% EBITDA margin and 54% gross margins.
→The base business is expected to continue driving growth, focusing on increasing market share, operational efficiency, and capacity utilization in existing facilities without large capex.
→Incremental capex is limited to debottlenecking for high-margin products; no major greenfield expansions planned.
→R&D revival includes plans to file 4-5 new DMFs per year from FY27, with revenue impact expected by FY29-FY30.
→The company targets becoming debt-free by FY29, supporting financially stable growth.
→The ibuprofen business is generating negative EBITDA; strategic options are being evaluated with outcomes expected in the next two quarters, impacting future profit dynamics.

See what Solara Active Pharma Sciences Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available).
→Incremental capex being done to debottleneck lines for high-margin products and improve cycle times.
→No big capex projects; emphasis on "smart and wise" use of existing capacity.
→No current plans for additional capital raising beyond the recent rights issue; company aims to be debt-free by FY '29.
→Vizag facility mothballed; future use under strategic evaluation (options include potentially repositioning as multipurpose or high-potent API block).
→R&D investment of about INR 25 crores annually starting FY '26, to file 4–5 new DMFs per year with commercial impact expected FY '29 onwards.
→The ibuprofen business may require strategic decisions including potential sale or technology change but no major capex planned there under current approach.

💰 Fundraising & Capital Structure

→After the recently completed rights issue, there are no further plans to raise additional capital through equity or debt at this time. (Page 13)
→The company aims to become debt-free by FY '29, targeting both long-term and working capital debt elimination. (Page 13)
→No major future fundraising activities for growth or debt paydown are expected in the next 2-3 years based on current plans. (Page 13)

See what Solara Active Pharma Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The base business of Solara has a very healthy order book, which is encouraging for sustained performance.
→There is no specific quantitative figure disclosed for the current order book size.
→The company is focused on expanding the existing business by seeding new customers for existing products, indicating ongoing and future orders.
→CRAMS business remains subscale with annual revenues around INR 10-12 crores and lacks a strong order pipeline currently.
→New product filings (4-5 DMFs annually) are planned, but meaningful revenue impact from these is expected around FY29-FY30.
→Vizag facility remains mothballed; no current revenues; strategic options for this facility and ibuprofen business are under evaluation with clarity expected by H1 FY27.
→Utilization across existing facilities is around 70%, leaving approximately 30% capacity to absorb incremental orders without significant new capex.

Key Metrics

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Solara Active Pharma Sciences Ltd Q4 FY26 results?

What is Solara Active Pharma Sciences Ltd share price analysis?

Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 573.4 with a market cap of ₹2,448 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active Pharma Sciences Ltd planning capital expenditure?

No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available).

Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.